Back to User profile » Prof. Dr. In-Jin Jang

Papers published by Prof. Dr. In-Jin Jang:


Pharmacokinetics, Tolerability and Pharmacogenetics of DA-8031 After Multiple Ascending Doses in Healthy Male Subjects

Hwang S, Lee DY, Cho JY, Chung JY, Jang IJ, Yu KS, Lee S

Drug Design, Development and Therapy 2021, 15:2375-2384

Published Date: 1 June 2021

Pharmacokinetic/Pharmacodynamic Interactions Between Evogliptin and Glimepiride in Healthy Male Subjects

Yoo H, Kim Y, Jang IJ, Yu KS, Lee S

Drug Design, Development and Therapy 2020, 14:5179-5187

Published Date: 24 November 2020

Pharmacokinetic/Pharmacodynamic Interaction Between Evogliptin and Pioglitazone in Healthy Male Subjects

Hwang I, Kim Y, Yoo H, Jang IJ, Yu KS, Lee S

Drug Design, Development and Therapy 2020, 14:4493-4502

Published Date: 23 October 2020

Pharmacokinetic interaction between fimasartan and atorvastatin in healthy male volunteers

Choi Y, Lee S, Jang IJ, Yu KS

Drug Design, Development and Therapy 2018, 12:2301-2309

Published Date: 24 July 2018

Pharmacokinetic characteristics of telaprevir in healthy Korean male subjects and comparisons with Japanese

Choi Y, Yoon S, Matsumoto K, Ohta Y, Lee S, Yu KS, Jang IJ

Drug Design, Development and Therapy 2018, 12:1045-1051

Published Date: 30 April 2018

Pharmacokinetics and tolerability of eletriptan hydrobromide in healthy Korean subjects

Kim YK, Shin KH, Alderman J, Yu KS, Jang IJ, Lee S

Drug Design, Development and Therapy 2018, 12:331-337

Published Date: 19 February 2018

Pharmacokinetics and tolerability of DA-8031, a novel selective serotonin reuptake inhibitor for premature ejaculation in healthy male subjects

Shin D, Lee S, Yi S, Yoon SH, Cho JY, Bahng MY, Jang IJ, Yu KS

Drug Design, Development and Therapy 2017, 11:713-723

Published Date: 10 March 2017

The influence of dietary sodium content on the pharmacokinetics and pharmacodynamics of fimasartan

Gu N, Cho JY, Shin KH, Jang IJ, Rhee MY

Drug Design, Development and Therapy 2016, 10:1525-1531

Published Date: 19 April 2016

A pharmacokinetic comparison of two voriconazole formulations and the effect of CYP2C19 polymorphism on their pharmacokinetic profiles

Chung H, Lee H, Han H, An H, Lim KS, Lee YJ, Cho JY, Yoon SH, Jang IJ, Yu KS

Drug Design, Development and Therapy 2015, 9:2609-2616

Published Date: 13 May 2015

Effect of renal function on the pharmacokinetics of fimasartan: a single-dose, open-label, Phase I study

Kim S, Lee J, Shin D, Lim KS, Kim YS, Jang IJ, Yu KS

Drug Design, Development and Therapy 2014, 8:1723-1731

Published Date: 6 October 2014

Multiple-dose pharmacokinetics and pharmacodynamics of evogliptin (DA-1229), a novel dipeptidyl peptidase IV inhibitor, in healthy volunteers

Gu N, Park MK, Kim TE, Bahng MY, Lim KS, Cho SH, Yoon SH, Cho JY, Jang IJ, Yu KS

Drug Design, Development and Therapy 2014, 8:1709-1721

Published Date: 6 October 2014

Novel nanocrystal formulation of megestrol acetate has improved bioavailability compared with the conventional micronized formulation in the fasting state

Jang K, Yoon S, Kim SE, Cho JY, Yoon SH, Lim KS, Yu KS, Jang IJ, Lee H

Drug Design, Development and Therapy 2014, 8:851-858

Published Date: 25 June 2014